CELEX: 62018TN0347
Language: en
Date: 2018-06-01 00:00:00
Title: Case T-347/18: Action brought on 1st of June 2018 — Laboratoire Pareva and Biotech3D v Commission

201807270102025322018/C 285/533472018TC28520180813EN01ENINFO_JUDICIAL20180601373711Case T-347/18: Action brought on 1st of June 2018 — Laboratoire Pareva and Biotech3D v Commission
 ---documentbreak--- C2852018EN3710120180601EN0053371371Action brought on 1st of June 2018 — Laboratoire Pareva and Biotech3D v Commission
   (Case T-347/18)2018/C 285/53Language of the case: English
      Parties
   
   
      Applicants: Laboratoire Pareva (Saint Martin de Crau, France) and Biotech3D Ltd & Co. KG (Gampern, Austria) (represented by: K. Van Maldegem and S. Englebert, lawyers)
   
      Defendant: European Commission
   
      Form of order sought
   
   
            —
         
         
            declare the application admissible and well-founded;
         
      
            —
         
         
            annul the European Commission’s Implementing Regulation (EU) 2018/613 (
                  1
               ) of 20 April 2018 approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 2 and 4 under Regulation 528/2012 (
                  2
               ) (the ‘Contested Act’); and
         
      
            —
         
         
            order the defendant to pay the costs of these proceedings.
         
      
      Pleas in law and main arguments
   
   In support of the action, the applicants rely on three pleas in law which are in essence identical or similar to those relied on in Case T-337/18, Laboratoire Pareva v Commission.
   
   (
         1
      )	Commission Implementing Regulation (EU) 2018/613 of 20 April 2018 approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 2 and 4 (OJ 2018, L 102, p. 1)
   (
         2
      )	Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ 2012, L 167, p. 1)